Stock MVIR B MEDIVIR AB
Add to a list
To use this feature you must be a member
Log inSign up

Company Medivir AB

Equities

MVIR B

SE0020181014

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:38 2024-04-19 am EDT 		5-day change 1st Jan Change
2.67 SEK -0.37% Intraday chart for Medivir AB -0.37% -6.32%
Mar. 21 Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 21-MAR-2024. CI
Feb. 22 Medivir Presents Data That Strengthens the Fostrox/Lenvima Combination in Primary Liver Cancer At Easl Liver Cancer Summit CI

Business Summary

Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.

Number of employees: 10

Sales per Business

SEK in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
4 100.0 % 8 100.0 % +73.16%

Sales per region

SEK in Million2022Weight2023Weight Delta
United States
46.9 %
-- 4 46.9 % -
Europe, Other
43.3 %
4 80.8 % 3 43.3 % -7.16%
Rest of the World
4.8 %
0 9.9 % 0 4.8 % -16.21%
Sweden
2.5 %
0 5.0 % 0 2.5 % -13.12%
Nordic Region, Other
2.4 %
0 4.2 % 0 2.4 % -0.53%

Managers

Managers TitleAgeSince
Jens Lindberg CEO
 Chief Executive Officer 53 22-01-23
Magnus Christensen DFI
 Director of Finance/CFO 50 19-08-11
Uli Alf Hacksell CHM
 Chairman 74 18-05-02
Pia Baumann CTO
 Chief Tech/Sci/R&D Officer 58 23-02-19
Malene Jensen CTO
 Chief Tech/Sci/R&D Officer 54 21-09-30
Fredrik Öberg CTO
 Chief Tech/Sci/R&D Officer 59 10-12-31
Yilmaz Mahshid BRD
 Director/Board Member 45 20-05-25

Members of the board

Members of the board TitleAgeSince
Uli Alf Hacksell CHM
 Chairman 74 18-05-02
Stig Lennart Hansson BRD
 Director/Board Member 68 18-05-02
Yilmaz Mahshid BRD
 Director/Board Member 45 20-05-25
Bengt Westermark BRD
 Director/Board Member 79 17-05-02

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 864,750 0 864,750 ( 100.00 %) 68.69 %
Stock B 1 104,506,048 72,375,356 ( 69.25 %) 11,413 ( 0.0109 %)

Shareholders

NameEquities%Valuation
Nordea Investment Management AB
9.226 %
10,338,122 9.226 % 3 M kr
Livförsäkringsbolaget Skandia, ömsesidigt
0.8466 %
948,688 0.8466 % 243 765 kr
Uli Alf Hacksell
0.4902 %
549,265 0.4902 % 141 134 kr
FCG Fonder AB
0.3350 %
375,361 0.3350 % 96 449 kr
Alfred Berg Kapitalförvaltning AB
0.1712 %
191,825 0.1712 % 49 289 kr
Storebrand Asset Management AS
0.0968 %
108,418 0.0968 % 27 858 kr
Swedbank Robur Fonder AB
0.0828 %
92,732 0.0828 % 23 827 kr
Delta Lloyd Asset Management NV
0.0724 %
81,137 0.0724 % 20 848 kr
Holberg Fondsforvaltning AS
0.0517 %
57,952 0.0517 % 14 891 kr
Gustavia Fonder AB
0.0417 %
46,750 0.0417 % 12 012 kr

Company contact information

Medivir AB

Lunastigen 5 2nd Floor

141 22, Huddinge

+46 8 54 68 31 00

http://www.medivir.com
address Medivir AB(MVIR B)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Medivir AB

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.68 SEK
Average target price
20.55 SEK
Spread / Average Target
+666.95%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MEDIVIR AB Stock Medivir AB
-6.32% 27.49M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.10% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.11% 96.07B
ARGENX SE Stock argenx SE
-1.80% 21.66B
BIONTECH SE Stock BioNTech SE
-17.75% 20.77B
GENMAB A/S Stock Genmab A/S
-6.91% 18.53B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.00% 16.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-28.19% 13.79B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.18% 13.33B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+19.90% 10.94B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MVIR B Stock
  4. Company Medivir AB